Skip to main content

Drug Repurposing and Repositioning Workshop Summary (2014) / Chapter Skim
Currently Skimming:

Appendix A: Workshop Agenda
Pages 65-72

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 65...
... • To evaluate the business models and economic incentives for pursuing a repurposing approach. • To discuss how genomic and genetic research could be positioned to better enable a drug repurposing paradigm.
Read the entire page →
From page 66...
... Terry, Roundtable Co-Chair President and Chief Executive Officer Genetic Alliance Geoffrey Ginsburg, Roundtable Co-Chair Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy; Executive Director, Center for Personalized Medicine, Duke Medicine; Professor of Medicine and Pathology, Duke University Medical Center 8:35–8:40 A.M. Charge to Workshop Speakers and Participants Aidan Power, Workshop Chair Vice President and Head, PharmaTx Precision Medicine Pfizer Inc.
Read the entire page →
From page 67...
... SESSION II: ENABLING TOOLS AND –12:30 P.M. TECHNOLOGY Moderator: Geoffrey Ginsburg Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy; Executive Director, Center for Personalized Medicine, Duke Medicine; Professor of Medicine and Pathology, Duke University Medical Center 10:35–10:55 A.M.
Read the entire page →
From page 68...
... Lon Cardon Senior Vice President, Alternative Discovery and Development GlaxoSmithKline 11:15–11:30 A.M. Government-Sponsored Efforts: NCATS John McKew Acting Director, Division of Pre-Clinical Innovation National Center for Advancing Translational Sciences 11:30–11:45 A.M.
Read the entire page →
From page 69...
... Latty Professor of Law Duke University 3:00–3:15 P.M. Strategies for Overcoming Barriers to Drug Repurposing: NCATS Christine Colvis Director, Extramural Therapeutics Discovery National Center for Advancing Translational Sciences
Read the entire page →
From page 70...
... Respondents: Ronald J Bartek President Friedreich's Ataxia Research Alliance Lon Cardon Senior Vice President, Alternative Discovery and Development GlaxoSmithKline Christine Colvis Director, Extramural Therapeutics Discovery National Center for Advancing Translational Sciences
Read the entire page →
From page 71...
... SESSION VI: CONCLUSION 5:15–5:30 P.M. CONCLUDING REMARKS Aidan Power, Workshop Chair Vice President and Head, PharmaTx Precision Medicine Pfizer Inc.
Read the entire page →

Key Terms

  • aidan power
  • workshop chair
  • chair director
  • enabling tools
  • repurposing drugs

  • current landscape
  • arti rai
  • scientific affairs
  • drug discovery
  • therapeutics discovery

  • training center
  • latty professor
  • hughes medical
  • economic incentives
  • executive vice

  • thomas executive
  • ataxia research
  • value proposition
  • repurposing paradigm
  • howard hughes

  • duke institute
  • officer genetic
  • advancing repurposing
  • extramural therapeutics
  • concluding remarks

  • pfizer inc
  • medicines unit
  • medical institute
  • assistant vice
  • cancer center


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.